Treatment of GH-deficient children with two different GH doses: effect on final height and cost–benefit implications

Giorgio Radetti, Fabio Buzi, Claudio Paganini, Alba Pilotta and Barbara Felappi

Department of Paediatrics, Regional Hospital of Bolzano, via I. Boehler No. 5, 39100 Bolzano, Italy and Department of Paediatrics, University of Brescia, Brescia, Italy

(Consultation should be addressed to G Radetti; Email: giorgio.radetti@asbz.it)

Abstract

Objective: Treatment of GH-deficient (GHD) children with higher doses of recombinant human GH (rhGH) than conventional ones has been reported to result in higher growth velocity and increased final height. These findings, however, were observed by comparing large but heterogeneous groups of children. We wanted to verify whether the same results could be obtained in two groups of appropriately well-matched children with isolated GHD treated with high vs conventional doses of rhGH.

Methods: Out of two cohorts of GHD children, cohort A (on a weekly rhGH dose of 0.3 mg/kg body weight) and cohort B (on a weekly rhGH dose of 0.15 mg/kg body weight), we selected two groups, each including 13 patients, who before treatment were matched for age, sex and height standard deviation score (SDS). They were followed up until final height.

Results: Final height SDS was significantly higher in group A (2.06±0.45 vs 2.17±0.7; P=0.008) as well as height gain SDS (1.81±0.58 vs 1.21±0.62; P=0.002). The difference between final height SDS and target height SDS was positive only in group A and significantly higher in group A than in group B (0.33±0.51 vs −0.46±0.7; P=0.01). Glucose tolerance was always normal in the group treated with higher doses.

Conclusion: The final height of children treated with higher doses of rhGH is increased, also in relation to their genetic target. The economical burden of this choice of treatment, however, has to be taken into account when evaluating the results.

European Journal of Endocrinology 148 515–518

Introduction

The introduction of growth hormone (GH) therapy in the late 1950s significantly modified the statural outcome of children affected by GH deficiency (GHD), and even more so following the introduction over a decade ago of recombinant human GH (rhGH), which allowed GHD patients to be treated with higher doses of GH with greater consistency (1).

Clinical studies have shown that early diagnosis and treatment, bone age (BA) retardation, height at diagnosis and at pubertal onset, severity of GHD and higher daily doses of GH all have a positive influence on adult stature (2–6). It is, however, still a matter of debate whether treatment with higher GH doses (0.3 mg/kg per week) should be preferred to the conventional (0.15–0.20 mg/kg per week). Discordant results have been reported with the higher dosage (6, 7), mainly due to the fact that these multicentre studies dealt with different study populations (8). We could not find any reports in the literature comparing the effects of conventional vs high GH doses on the final height in two groups of well-matched children, with the same genetic potential. There are only some medium-term studies, which, however, reported discordant results (9–11). We therefore thought that it would be of interest to study the final height of two groups of well-matched children affected by isolated GHD, treated with high or conventional rhGH doses.

Subjects and methods

Out of two cohorts of GHD children (cohort A: 85 patients treated at the Regional Hospital of Bolzano, with a weekly rhGH dose of 0.3 mg/kg body weight; cohort B: 73 patients treated at the Paediatric Unit, University of Brescia, with a weekly rhGH dose of 0.15 mg/kg body weight), we selected two groups (group A and group B respectively), each including 13 children, who, at the beginning of treatment, were matched for age, sex and height standard deviation score (SDS). Matching criteria (see Table 1) included: age difference not greater than 1 year and height SDS...
difference not greater than 1. There was no difference in life style and eating habits between the two groups. They were followed-up until final height was reached, the latter being evaluated when BA was more than 17 years in boys and 15 years in girls and when no further height gain was observed for 6 months. Overall, treatment lasted 5.4 ± 1.4 years in group A and 5.1 ± 1.2 years in group B, and in each group the same rhGH dose per kg was maintained throughout the whole study. The diagnosis of GHD was based on the following criteria: height less than −2 SDS or <10th percentile when corrected for parental target (according to J M Tanner’s ‘Parents-allowed-for charts’) (12); height velocity < 25th percentile for chronological age when measured for more than 1 year; BA delay > 2 years compared with chronological age; peak GH < 10 μg/l in at least two consecutive conventional pharmacological tests (insulin tolerance test, arginine- or clonidine-stimulation test). In particular, none of the patients had any organic GHD, panhypopituitarism or multiple pituitary hormone deficiency, all being affected by idiopathic isolated GHD, as confirmed by full endocrine evaluation and either pituitary computerized tomography or nuclear magnetic resonance. Peak GH after pharmacological stimulation was similar in the two groups (group A, 4.9 ± 2.5 μg/l; group B 5.4 ± 2.7 μg/l). At the beginning of the study all patients were pre-pubertal, and all progressed regularly through puberty during the study until complete pubertal maturation. All group A patients (higher GH dose) underwent once a year an oral glucose tolerance test (OGTT) in order to assess possible changes in glucose tolerance.

The following auxological variables were considered: height, expressed as SDS (13); BA, evaluated according to the Greulich & Pyle atlas (14); target height (TH), calculated as sex-corrected mid-parental height expressed in SDS units; height gain calculated as final height SDS minus height SDS at the beginning of treatment; and finally the difference between final height SDS and TH SDS. Clinical characteristics at the beginning are shown in Table 2. In particular, there was no significant difference in mean BA and mean TH SDS between the two groups, indicating that they showed the same genetic potential.

The study protocol was approved by the local Ethical Committees and informed consent was obtained from the parents only for the children treated with high rhGH dosage.

**Statistical analysis**

Student’s unpaired t-test was used to evaluate possible differences in the above mentioned variables between the two groups. P < 0.05 was considered statistically significant. Values are reported as means ± S.D.

**Results**

Final height was significantly higher in group A ($P = 0.0008$) (Table 3), as well as height gain ($P = 0.002$). The difference between final height and TH was positive only in group A and significantly higher in group A than in group B ($P = 0.01$).

The OGTT was always normal in the group treated with higher doses.

**Discussion**

Our study clearly shows that the final height of GHD children treated with higher doses of rhGH is increased compared with those receiving conventional treatment. The children in the high-dose group grew taller not only in absolute terms, but also in accordance with their genetic potential. In fact only the high-dose group significantly surpassed TH. We observed

### Table 1 Matching table. The progression number refers to the recruitment order for each pair of subjects.

<table>
<thead>
<tr>
<th>Pair</th>
<th>Sex</th>
<th>Age Group A</th>
<th>Age Group B</th>
<th>Height SDS Group A</th>
<th>Height SDS Group B</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>f</td>
<td>11.3</td>
<td>10.6</td>
<td>−2.75</td>
<td>−2.20</td>
</tr>
<tr>
<td>2</td>
<td>m</td>
<td>13.3</td>
<td>12.5</td>
<td>−2.40</td>
<td>−2.00</td>
</tr>
<tr>
<td>3</td>
<td>f</td>
<td>11.8</td>
<td>10.9</td>
<td>−2.40</td>
<td>−1.89</td>
</tr>
<tr>
<td>4</td>
<td>m</td>
<td>13.8</td>
<td>14.1</td>
<td>−2.23</td>
<td>−2.10</td>
</tr>
<tr>
<td>5</td>
<td>m</td>
<td>13.9</td>
<td>13.8</td>
<td>−3.23</td>
<td>−3.10</td>
</tr>
<tr>
<td>6</td>
<td>m</td>
<td>13.1</td>
<td>13.9</td>
<td>−1.57</td>
<td>−2.40</td>
</tr>
<tr>
<td>7</td>
<td>m</td>
<td>11.8</td>
<td>12.1</td>
<td>−2.61</td>
<td>−2.14</td>
</tr>
<tr>
<td>8</td>
<td>m</td>
<td>9.7</td>
<td>9.3</td>
<td>−1.64</td>
<td>−2.10</td>
</tr>
<tr>
<td>9</td>
<td>m</td>
<td>8.6</td>
<td>8.6</td>
<td>−1.81</td>
<td>−1.59</td>
</tr>
<tr>
<td>10</td>
<td>m</td>
<td>14.3</td>
<td>14.8</td>
<td>−2.46</td>
<td>−1.99</td>
</tr>
<tr>
<td>11</td>
<td>m</td>
<td>10.8</td>
<td>9.9</td>
<td>−2.21</td>
<td>−2.27</td>
</tr>
<tr>
<td>12</td>
<td>m</td>
<td>8.9</td>
<td>8.7</td>
<td>−2.54</td>
<td>−1.65</td>
</tr>
<tr>
<td>13</td>
<td>f</td>
<td>9.8</td>
<td>9.8</td>
<td>−1.59</td>
<td>−2.47</td>
</tr>
</tbody>
</table>

### Table 2 Clinical characteristics of the patients at the beginning of treatment.

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>BA (years)</th>
<th>Sex (M/F)</th>
<th>Height (SDS)</th>
<th>TH (SDS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group A</td>
<td>11.6 ± 1.9</td>
<td>9.0 ± 2.3</td>
<td>10/3</td>
<td>−2.26 ± 0.49</td>
</tr>
<tr>
<td>Group B</td>
<td>11.5 ± 2.2</td>
<td>8.8 ± 2.3</td>
<td>10/3</td>
<td>−2.30 ± 0.59</td>
</tr>
<tr>
<td>P</td>
<td>NS</td>
<td>NS</td>
<td></td>
<td>NS</td>
</tr>
</tbody>
</table>

### Table 3 Clinical characteristics of the patients at final height.

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>FH (SDS)</th>
<th>Height gain (SDS)</th>
<th>FH—TH (SDS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group A</td>
<td>18.4 ± 1.67</td>
<td>−0.45 ± 0.36</td>
<td>1.81 ± 0.58</td>
</tr>
<tr>
<td>Group B</td>
<td>17.2 ± 1.2</td>
<td>−1.07 ± 0.70</td>
<td>1.23 ± 0.62</td>
</tr>
<tr>
<td>P</td>
<td>0.008</td>
<td>0.002</td>
<td>0.01</td>
</tr>
</tbody>
</table>

FH, final height.
a difference in final height, corrected for the parental height, of 0.79 SDS, which roughly corresponds to 5.9 cm.

Our results agree with those of other larger studies reporting a positive relationship between increasing GH doses and improvement in adult height (2–6) and suggest that a GH dose of 0.3 mg/kg per week is more effective than that of 0.15 mg/kg per week. This is also in agreement with the findings of Blethen et al. (6), but not with those of August et al. (7). However, it has been suggested (3) that the better results obtained in The Genentech Growth Study Group study (6) were no longer apparent when the mid-parental height was taken into account. We can only comment that it is rather difficult to compare the results of two different regimens of GH obtained in two not well-matched samples.

Overall, according to the literature (2–6) and from our own findings, it seems that the more GH you give, the taller the child will be. Stanhope et al. (15) and MacGillivray et al. (16), however, were not able to improve the adult height of a group of GHD children by increasing the GH doses from 5 mg/m^2^ per week to 10 mg/m^2^ per week only at the beginning of puberty, suggesting that intensive treatment needs to be started during the prepubertal period in order to be effective, unless very high doses of GH (0.7 mg/kg per week) are employed during puberty, as proposed by Mauras et al. (17).

There are, however, some considerations to be made. First the cost of doubling the dose. We calculated that for one child, considering the mean difference of 5.9 cm and a mean period of 5 years of therapy, each centimetre ultimately costs 27 368 Euro. If we consider the situation in Italy, where around 5500 children are currently being treated with the conventional GH dosage, the difference in cost between the two regimens, calculated with the same criteria, would amount to 150 524 000 Euro. Therefore this should seriously be taken into consideration before raising the dosage.

Some potential side-effects should also be taken into account. It is well known, in fact, that GH excess has a negative influence on glucose tolerance, and recently it has been reported that GH treatment of GHD children can advance the onset of diabetes mellitus, at least in an already predisposed population (18). We did not find, however, any signs of glucose intolerance in our patients. Moreover, the potential side-effects of high-dose GH treatment on the cardiovascular system have not as yet been fully clarified (19). The theoretical risk of an increased incidence of adulthood cancer associated with an elevated serum insulin-like growth factor (IGF-I) level in a GH recipient, is, however, lowered by the fact that GH also increases the level of IGF-binding protein-3, which would inhibit IGF-I action (20). Other possible side-effects, such as benign intracranial hypertension, prepubertal gynaecomastia, arthralgia and oedema, are very rare in children (21), and were not seen in our study population. In conclusion, the use of rhGH, with its unlimited supply, allows a more intensive treatment of GHD children, leading to a better final outcome, although at a questionable cost.

References
17. Mauras N, Artie KM, Reiter EO, Suenger P & Baptist J. High dose recombinant human growth hormone (GH) treatment
of GH-deficient patients in puberty increases near-final height: a
randomized, multicenter trial. Genentech, Inc., Cooperative
Study Group. Journal of Clinical Endocrinology and Metabolism

18 Cutfield WS, Wilson P, Bennmarker H, Albertsson Wikland K,
Chatelain P & Ranke MB. Incidence of diabetes mellitus and
impaired glucose tolerance in children and adolescents receiving

19 Radetti G, Crepaz R, Paganini C, Gentili L & Pitscheider W.
Medium-term cardiovascular effects of high-dose growth
hormone treatment in growth hormone deficient children.

20 Cohen P, Clemmons DR & Rosenfield RG. Does the GH–IGF axis
play a role in cancer pathogenesis? Growth Hormone Research
2000 10 297–305.

21 GH Research Society. Consensus guidelines for the diagnosis and
treatment of growth hormone (GH) deficiency in childhood and
adolescence: summary statement of the GH Research Society.
Journal of Clinical Endocrinology and Metabolism 2000 85
3990–3993.

Received 26 August 2002
Accepted 20 February 2003